title: [Expression of c-erbB-2 and topoisomerase II alpha in relation to chemoresistance in ovarian cancer].
abstract: In the present study, we examined die role of c-erbB-2 for chemoresistance in ovarian cancer. Overexpression of c-erbB-2 mRNA in tumor tissue was associated with a shorter survival of patients with primary ovarian cancer (P = 0.0001, N = 77) and was an independent prognostic factor in the proportional-hazard model (P = 0.035). A significant association between expression of c-erbB-2 mRNA und survival was obtained for the subgroup of patients who received a standard chemotherapy with carboplatin or cisplatin and cyclophosphamide (P = 0.0003). In addition, the application of a standard chemotherapy improved the survival of patients with relatively low c-erbB-2 expression (P = 0.013), but not of patients with overexpression of c-erbB-2 (P = 0.359). Expression of c-erbB-2 mRNA correlated with expression of topoisomerase IIalpha mRNA determined by a reverse semiquantitative PCR technique (P = 0.009), whereas expression of c-erbB-2 und topoisomerase IIbeta mRNA dit not correlate (P = 0.221). The data suggest that topoisomerase IIalpha, which correlates with c-erbB-2 expression, contributes to the resistance of c-erbB-2-overexpressing carcinomas.
authors.affiliation: Universitätsfrauenklinik Mainz, Langenbeckstasse 1, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Tanner
authors.forename: H
authors.initials: H
authors.lastname: Pilch
authors.forename: U
authors.initials: U
authors.lastname: Schäffer
authors.forename: A
authors.initials: A
authors.lastname: Franzen
authors.forename: R
authors.initials: R
authors.lastname: Seufert
authors.forename: J G
authors.initials: JG
authors.lastname: Hengstler
mesh_terms: D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004268:DNA-Binding Proteins; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D015996:Survival Rate
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D003520:Cyclophosphamide; D016190:Carboplatin; D004250:DNA Topoisomerases, Type II; D002945:Cisplatin
vernacular_title: Die Expression von c-erbB-2 und Topoisomerase IIalpha in Relation zur Zytostatikaresistenz beim Ovarialkarzinom.